DeepMed Research

Cytokinetics

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 564

Market Cap: $6.5B

Website

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 3

Terminated

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Reldesemtiv
Drug: Placebo

First Posted Date: 2021-06-30

Last Posted Date: 2024-12-05

Lead Sponsor: Cytokinetics

Target Recruit Count: 489

Registration Number: NCT04944784

Locations: 🇺🇸
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 81 locations

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Phase 2

Conditions: Symptomatic Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: Aficamten (5 - 20 mg)

First Posted Date: 2021-04-19

Last Posted Date: 2025-04-02

Lead Sponsor: Cytokinetics

Target Recruit Count: 900

Registration Number: NCT04848506

Locations: 🇩🇰
Copenhagen University Hospital, Copenhagen, Denmark
🇫🇷
Hopital de la Timone Service de cardiologie, Marseille, France
🇫🇷
CHU de Nantes Institut Du Thorax et du systeme nerveux Clinique Cardiologique et des Maladies Vasculaires, Nantes, France

and more 86 locations

Omecamtiv Mecarbil Post-trial Access Study

Phase 3

Withdrawn

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Omecamtiv mecarbil

First Posted Date: 2020-07-09

Last Posted Date: 2021-07-30

Lead Sponsor: Cytokinetics

Registration Number: NCT04464525

Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM

Phase 2

Completed

Conditions: Hypertrophic Cardiomyopathy (HCM)

Interventions: Drug: CK-3773274 (5 - 15 mg)
Drug: CK-3773274 (10 - 30 mg)
Drug: Placebo for CK-3773274

First Posted Date: 2020-01-07

Last Posted Date: 2025-03-25

Lead Sponsor: Cytokinetics

Target Recruit Count: 96

Registration Number: NCT04219826

Locations: 🇺🇸
New York University Langone Health Medical Center, New York, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Intermountain Medical Center, Murray, Utah, United States

and more 19 locations

Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults

Phase 1

Completed

Conditions: QT Intervals Changes
QTc Intervals Changes

Interventions: Drug: Omecamtiv Mecarbil (OM)
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2019-11-25

Last Posted Date: 2025-03-30

Lead Sponsor: Cytokinetics

Target Recruit Count: 70

Registration Number: NCT04175808

Locations: 🇬🇧
Research Site, Leeds, United Kingdom

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy Subjects
Symptomatic Obstructive Hypertrophic Cardiomyopathy

Interventions: Drug: Placebo - Granules in Capsule
Drug: CK-3773274 - Granules in Capsule
Drug: CK-3773274 - Tablets

First Posted Date: 2018-12-07

Last Posted Date: 2025-01-24

Lead Sponsor: Cytokinetics

Target Recruit Count: 114

Registration Number: NCT03767855

Locations: 🇺🇸
Clinical Site, Tempe, Arizona, United States

Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure

Phase 3

Completed

Conditions: Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Omecamtiv Mecarbil
Drug: Placebo

First Posted Date: 2018-11-30

Last Posted Date: 2023-03-07

Lead Sponsor: Cytokinetics

Target Recruit Count: 276

Registration Number: NCT03759392

Locations: 🇺🇸
Alaska Heart and Vascular Institute, Anchorage, Alaska, United States
🇺🇸
Glacier View Research Institute, Cardiology, Kalispell, Montana, United States
🇨🇦
Mcgill University Health Centre (MUHC)-The Montreal General Hospital (MGH), Montreal, Quebec, Canada

and more 78 locations

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2

Completed

Conditions: Amyotrophic Lateral Sclerosis

Interventions: Drug: Reldesemtiv
Drug: Placebo

First Posted Date: 2017-05-19

Last Posted Date: 2020-09-11

Lead Sponsor: Cytokinetics

Target Recruit Count: 458

Registration Number: NCT03160898

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Neurology Associates, P.C., Lincoln, Nebraska, United States
🇺🇸
West Virginia University, Dept. of Neurology, Morgantown, West Virginia, United States

and more 60 locations

A Study for Patients Who Completed VITALITY-ALS (CY 4031)

Phase 3

Completed

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Interventions: Drug: tirasemtiv

First Posted Date: 2016-10-18

Last Posted Date: 2021-06-15

Lead Sponsor: Cytokinetics

Target Recruit Count: 280

Registration Number: NCT02936635

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
The Emory Clinic, Atlanta, Georgia, United States

and more 64 locations

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Phase 3

Completed

Conditions: Heart Failure

Interventions: Drug: Omecamtiv Mecarbil
Drug: Placebo
Drug: Standard of Care

First Posted Date: 2016-10-11

Last Posted Date: 2021-11-05

Lead Sponsor: Cytokinetics

Target Recruit Count: 8256

Registration Number: NCT02929329

Locations: 🇬🇧
Research Site, Worcester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy